Stock Analiz

Celularity Inc CELU

Biotechnology: Pharmaceutical Preparations · IPO 2019 · data as of November 13, 2026

$0.63Market cap $20M
Open the interactive analysis →

Celularity Inc (CELU) is a healthcare company listed in the US with a market value of about $20M. In the twelve months to June 30, 2026 it had revenue of $19M and net income of -$46M, a net margin of -245.7%.

Its overall Stock Analiz score is 1.0 out of 5 (weak). The strongest part is future growth (3/5); the weakest is value (0/5).

Key numbers: 5-year revenue growth of 13% a year, a 5-year average ROIC of -166%. A discounted cash flow model with moderate assumptions puts its intrinsic value about 82% below the current price.

About Celularity

Celularity is listed in the US and classified in biotechnology: pharmaceutical preparations, IPO year 2019. Revenue went from $14M in 2020 to $27M in 2025, growth of about 13.2% a year. It was profitable in 2 of the last 7 years in our data. Its share count rose by 71% over three years (dilution for shareholders). It spends 57% of revenue on research and development.

Score: 1.0 / 5

Value0/5
Future growth3/5
Track record2/5
Financial health0/5
Shareholder returns0/5

Checks passed

  • 3-year revenue growth above 10% a year
  • Profit margin improving
  • Strong R&D investment or growth above 20%
  • 5-year revenue growth above 8% a year
  • ROE above 15%

Checks not passed

  • P/E below 25
  • P/E below the industry median
  • P/FCF below 20
  • Price below intrinsic value (DCF, moderate assumptions)
  • PEG below 1.5
  • Revenue growth above 10% last year
  • 3-year free cash flow growth above 10% a year
  • 5-year EPS growth above 10% a year

Valuation

P/E (TTM)—
Forward P/E—
P/FCF—
P/S1.1
P/B—
EV/EBITDA—
PEG—
Dividend yield0.00%
FCF yield—
Shareholder yield0.0%
Intrinsic value vs. price−82%

Growth and quality

Revenue growth (1 yr)-51.0%
Revenue growth (5 yrs, per year)13.2%
EPS growth (5 yrs, per year)—
FCF growth (3 yrs, per year)—
Net margin (5-yr avg.)-340.9%
ROIC (5-yr avg.)-166.4%
Profitable years (of last 10)2
Years paying a dividend—

Financials, last 7 years

Fiscal yearTTM2025202420232022202120202019
Revenue$19M$27M$54M$23M$18M$21M$14M—
Net income-$46M-$92M-$58M-$196M$14M-$100M-$208M$6M
Free cash flow——-$7M-$40M-$143M-$116M-$91M—
EPS (diluted)$-1.69$-3.59$-2.64$-11.02$0.95$-14.90$-113.10$1.00
Net margin-245.7%-345.4%-106.8%-862.0%79.0%-469.3%-1458.4%—
ROIC—-213.8%-341.9%-180.1%-9.7%-86.7%——

From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.

Frequently asked questions

Is Celularity stock undervalued?

Our DCF model with moderate assumptions puts its intrinsic value about 82% below the current market value. A model is a range, not a promise; try your own assumptions in the DCF calculator.

Does Celularity pay a dividend?

Not currently.

Is Celularity a good stock to buy?

We do not give buy or sell advice. Celularity scores 1.0 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.

Similar companies

Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.